BioSpace News Archive

Celmatix Inc., the leading women’s health biotech focused uniquely on ovarian biology, today announced members of its newly appointed Advisory Board.

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).

Cellphire, the global leader in long-term stabilization and storage of platelets, is proud to announce that the Armed Services Blood Program (ASBP) has awarded Cellphire President G. Michael Fitzpatrick, PhD, with the 2020 ASBP Lifetime Achievement Award for his service and significant contributions to ASBP and the warfighter.

Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced that the first healthy volunteers have received MORF-057 in a phase 1 clinical trial designed to evaluate MORF-057’s safety and pharmacokinetic profile in addition to predictive pharmacodynamic signals.

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S

Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient in the study.

Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedure

Freeline Therapeutics Holdings plc, a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announces their supply agreement with Thermo Fisher Scientific Inc..

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the use of the ThinPrep ® Pap Test™ PreservCyt ® Solution vial as an approved sample type for its B

Bio-Techne Corporation announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.